If you have commercial insurance, you may qualify for the Celgene Commercial Co-pay Program. If you qualify, your out-of-pocket co-pay responsibility will be $25(subject to annual benefit limit) for REVLIMID. This program provides up to $10,000 per calendar yearto help meet co-pay/co-insurance costs.
Full Answer
What financial assistance is available for patients with Revlimid?
Assistance BMS Access Support ® can help identify financial assistance programs for eligible patients who have been prescribed REVLIMID and who need help managing the cost of treatment. The appropriate program will depend on the patient’s coverage. Patients With Commercial (Private) Insurance
Where can I find more information about Celgene REMS programs?
If you would like to obtain more information about any of the Celgene-administered REMS programs, please click on the program name below: www.LenalidomideREMS.com, to learn more about the Lenalidomide REMS program. www.POMALYSTREMS.com, to learn more about the POMALYST REMS ® program.
Is Revlimid a registered trademark of Celgene?
REVLIMID ®, POMALYST ®, POMALYST REMS ®, IMiD ®, and associated logos are registered trademarks of Celgene Corporation, a Bristol-Myers Squibb Company. Access Support ® and the related logo are registered trademarks of Bristol-Myers Squibb Company. Other trademarks are property of their respective owners. Do not use REVLIMID during pregnancy.
Is Revlimid covered by insurance?
Depending on your patient’s insurance situation, there are programs and organizations that may help for REVLIMID. For eligible patients with commercial or private insurance (including healthcare exchanges),* co-pay responsibility for REVLIMID is reduced to $25 (subject to annual benefit limit).
What tier drug is Revlimid?
What drug tier is Revlimid typically on? Medicare prescription drug plans typically list Revlimid on Tier 5 of their formulary. Generally, the higher the tier, the more you have to pay for the medication.
How long does Revlimid work for multiple myeloma?
Results showed that patients receiving Revlimid lived 39 months without their disease worsening, compared with 20 months for the observation arm. This translated into a 54% reduction in the risk of disease progression or death.
What is the average cost of Revlimid?
Revlimid now costs around $17,000 a month. The drug is now produced by Bristol Myers Squibb, which bought Celgene two years ago.
Is Revlimid a Celgene drug?
Celgene's stalwart Revlimid jumped 11%, reaching $2.73 billion, thanks to the adoption of use in tandem with Takeda's Velcade and dexamethasone in previously untreated multiple myeloma patients.
How long does a person stay on Revlimid?
Revlimid is typically prescribed with the medication dexamethasone (Hemady). You'll usually continue with this dosage in 28-day cycles. And you'll likely keep taking Revlimid for as long as you tolerate the drug. If your condition worsens, your doctor may recommend stopping treatment.
What is the success rate of Revlimid?
Patients who took REVLIMID and dexamethasone continuously had a 75% response rate compared to 73% of patients who took REVLIMID and dexamethasone for only 18 months and 62% of patients who took the combination of melphalan, prednisone, and thalidomide.
What is the monthly cost of Revlimid?
Celgene launched Revlimid in 2005 at a price of $215 per pill. After more than 20 price hikes, the drug now costs $763 per pill, or $16,023 per month.
Why does Revlimid cost so much?
Because Revlimid is an oral cancer treatment and not a chemotherapy infusion, it's covered by the drug plan of those with insurance. Myeloma patients will tend to hit their drug maximums quickly too, which means that they face no co-pays for the drug for much of the year. Even so, the costs can be significant.
Is there a generic available for Revlimid?
Generic Versions of Revlimid and Velcade Now Available for Patients With Multiple Myeloma. In the first half of 2022, the Food and Drug Administration (FDA) approved generic versions of the two drugs most commonly used as the backbone of multiple myeloma combination therapies, Revlimid and Velcade.
Is Revlimid a high risk medication?
VO: REVLIMID (lenalidomide) may cause serious side effects, including risk to unborn babies, risk of low blood counts and blood clots. There are safety considerations to be aware of with REVLIMID. That is why REVLIMID is only available through a restricted distribution program, Lenalidomide REMS.
Is Revlimid considered chemo?
Revlimid | Chemotherapy Drug Information | Chemocare.com.
What does Revlimid do to your body?
Treatment with REVLIMID can cause swelling of the limbs (arms, hands, and feet) and skin, called edema. This swelling or puffiness of the tissue directly under your skin is caused by excess fluid trapped in your body's tissues. Edema is most commonly noticed in the hands, arms, feet, ankles, and legs.
What happens when you stop taking REVLIMID?
No, stopping Revlimid treatment doesn't cause withdrawal symptoms. Withdrawal symptoms weren't reported as a side effect in people taking the medication in clinical studies. But if you stop taking Revlimid, your condition could worsen. You could also experience more symptoms of the condition.
What happens if you stop treatment for multiple myeloma?
But when treatment stops working, myeloma cells start growing again. It's called a relapse. Relapse is common for people with multiple myeloma. In fact, this cancer is known as a “remitting and relapsing” disease.
How long can I take lenalidomide?
Adults—At first, 20 milligrams (mg) once a day. This medicine is taken on Days 1 to 21 of repeated 28-day cycles for up to 12 cycles. Your doctor may adjust your dose as needed. Children—Use and dose must be determined by your doctor.
What does REVLIMID do to your body?
Treatment with REVLIMID can cause swelling of the limbs (arms, hands, and feet) and skin, called edema. This swelling or puffiness of the tissue directly under your skin is caused by excess fluid trapped in your body's tissues. Edema is most commonly noticed in the hands, arms, feet, ankles, and legs.
Financial assistance
Depending on your patient’s insurance situation, there are programs and organizations that may help for REVLIMID.
Insurance-related assistance
Our Specialists are available to assist with each of the following steps in the insurance approval process for REVLIMID. §
What is Celgene's commitment to patients?
Underlying Celgene’s commitment to improve the lives of patients worldwide is our dedication to change the course of human health through bold pursuits in science and a promise to always put patients first. At Celgene, we believe that a commitment to medical progress must go hand-in-hand with a corresponding mission to help ensure that patients who can benefit from our discoveries have the opportunity to do so.
What is Celgene's mission?
Celgene realizes its mission of improving the lives of patients around the world through our pioneering patient access programs, significant investment in clinical studies, support for continuing medical education and partnerships with charities that share our commitment to patients.#N#Learn More
Patients With Commercial (Private) Insurance
The BMS Oncology Co-Pay Assistance Program helps commercially insured patients who have been prescribed select BMS medications with out-of-pocket deductibles, co-pays, or co-insurance requirements. Eligible patients may pay as little as $10 per one-month supply, up to a maximum of $15,000 per calendar year.
Patients With Insurance Through Federal Healthcare Programs
Patients insured through Federal Healthcare Programs are not eligible for co-pay assistance programs sponsored by Bristol Myers Squibb.
Patients Without Prescription Drug Coverage or Who Are Underinsured
For patients without prescription drug insurance or for patients who are underinsured, BMS Access Support can make a referral to independent charitable foundations that may be able to help.
How to contact Celgene?
Email us at [email protected] or fax 1-800-822-2496.
Is Revlimid recommended for MCL?
REVLIMID ® is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with CLL outside of controlled clinical trials.
How to contact Revlimid?
Your experience could help fellow patients, caregivers, and healthcare providers. To contact us, call 1-800-657-9801 or email [email protected].
What is Revlimid used for?
REVLIMID ® (lenalidomide) is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells).
What do you need to know before prescribing Revlimid?
Before you begin taking REVLIMID, you must read and agree to all of the instructions in the REVLIMID REMS ® program. Before prescribing REVLIMID, your healthcare provider will explain the REVLIMID REMS program to you and have you sign the Patient-Physician Agreement Form.
Is Revlimid a prescription?
REVLIMID ® (lenalidomide) is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation (a type of stem cell transplant that uses your own stem cells). REVLIMID should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not known if REVLIMID is safe and effective in children.
How old do you have to be to sign up for Revlimid?
Must be 18 years of age or older to sign up. Please see Privacy Policy to learn more about Bristol Myers Squibb's use of submitted information.
Is Revlimid safe for babies?
VO: REVLIMID (lenalidomide) may cause serious side effects, including risk to unborn babies, risk of low blood counts and blood clots. There are safety considerations to be aware of with REVLIMID. That is why REVLIMID is only available through a restricted distribution program, REVLIMD REMS ®. Please listen for important safety information throughout this video.
Can you breastfeed with Revlimid?
are breastfeeding. Do not breastfeed during treatment with REVLIMID. It is not known if REVLIMID passes into your breast milk and can harm your baby.
What is Celgene patient support?
Celgene Patient Support® is here to help you and your loved ones understand the financial help that may be available for REVLIMID®.
How to contact Celgene insurance?
Call your Specialist at 1-800-931-8691. If you have commercial insurance, you may qualify for the Celgene Commercial Co-pay Program. If you qualify, your out-of-pocket co-pay responsibility will be $25(subject to annual benefit limit) for REVLIMID.
Is Revlimid a trademark?
Celgene Patient Support®and REVLIMID are registered trademarks of Celgene Corporation. Other trademarks are the property of their respective owners. © 2019 Celgene Corporation 09/19 US-REV-19-0425
Contraindications
Warnings and Precautions
- Embryo-Fetal Toxicity: See Boxed WARNINGS. 1. Females of Reproductive Potential: See Boxed WARNINGS. 2. Males: Lenalidomide is present in the semen of patients receiving the drug. Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking REVLIMID and for up to 4 weeks after discontinuing REVLIMI…
Multiple Myeloma
- In newly diagnosed: The most frequently reported Grade 3 or 4 reactions included neutropenia, anemia, thrombocytopenia, pneumonia, asthenia, fatigue, back pain, hypokalemia, rash, cataract, lymphop...
- The most common adverse reactions reported in ≥20% (Arm Rd Continuous): diarrhea (45%), anemia (44%), neutropenia (35%), fatigue (33%), back pain (32%), asthenia (28%), insomnia (2…
- In newly diagnosed: The most frequently reported Grade 3 or 4 reactions included neutropenia, anemia, thrombocytopenia, pneumonia, asthenia, fatigue, back pain, hypokalemia, rash, cataract, lymphop...
- The most common adverse reactions reported in ≥20% (Arm Rd Continuous): diarrhea (45%), anemia (44%), neutropenia (35%), fatigue (33%), back pain (32%), asthenia (28%), insomnia (28%), rash (26%),...
- Maintenance Therapy Post Auto-HSCT:The most frequently reported Grade 3 or 4 reactions in ≥20% (REVLIMID arm) included neutropenia, thrombocytopenia, and leukopenia. The serious adverse reactions o...
- The most frequently reported adverse reactions in ≥20% (REVLIMID arm) across both mainte…
Drug Interactions
- Periodically monitor digoxin plasma levels due to increased Cmaxand AUC with concomitant REVLIMID therapy. Patients taking concomitant therapies such as ESAs or estrogen-containing therapies may have an increased risk of thrombosis. It is not known whether there is an interaction between dexamethasone and warfarin. Close monitoring of PT and INR is recommen…
Use in Specific Populations
- PREGNANCY: See Boxed WARNINGS:If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for f...
- LACTATION: There is no information regarding the presence of lenalidomide in human milk, the effects of REVLIMID on the breastfed infant, or the effects of REVLIMID on milk productio…
- PREGNANCY: See Boxed WARNINGS:If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for f...
- LACTATION: There is no information regarding the presence of lenalidomide in human milk, the effects of REVLIMID on the breastfed infant, or the effects of REVLIMID on milk production. Because many...
- RENAL IMPAIRMENT: Adjust the starting dose of REVLIMID based on creatinine clearance value and for patients on dialysis.